Form 4: Edwards Lifesciences Executive Andrew Dahl Reports Stock and Option Grants

Andrew Dahl, SVP, Corporate Controller at Edwards Lifesciences, reports the acquisition of restricted stock units and employee stock options.

Summary

• On May 8, 2025, Andrew M. Dahl, SVP, Corporate Controller of Edwards Lifesciences Corp, reported changes in beneficial ownership.
• Dahl acquired 3,335 shares of common stock at $0.00, and now beneficially owns 8,106.5266 shares.
• Dahl also acquired 5,670 employee stock options with an exercise price of $74.63, which vest in four equal annual installments starting May 8, 2026, and expire on May 7, 2032.
• These transactions were made under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.
• The report also includes a quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing reflecting compensation and insider transactions. The acquisition of shares and options by an executive is generally viewed as a positive, but it's a routine occurrence.

Positives

• The acquisition of stock and options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's value and prospects.

Stakeholder Impact

• Shareholders may view the insider transactions as a signal of management's confidence in the company.
• Employees participating in the Employee Stock Purchase Plan are also stakeholders affected by these transactions.

Key Dates

Keywords

Form 4, Beneficial Ownership, Edwards Lifesciences, Stock Options, Restricted Stock Units, Insider Trading